Spinal Muscular Atrophy Type 2Symptoms, Doctors, Treatments, Advances & More
Spinal Muscular Atrophy Type 2 Overview
Learn About Spinal Muscular Atrophy Type 2
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Department Of Neurology
Basil Darras is a Pediatric Neurologist practicing medicine in Boston, Massachusetts. Dr. Darras is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 1, and Gastrostomy.
Francesco Muntoni practices practicing medicine in London, United Kingdom. Mr. Muntoni is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Gastrostomy.
Office
Crystal Proud is a Pediatrics provider practicing medicine in Norfolk, Virginia. She has been practicing medicine for over 17 years. Dr. Proud is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 2. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, and Becker Muscular Dystrophy.
Summary: The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Summary: This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score...